EWING, NJ--(Marketwire - September 15, 2008) - DOR BioPharma, Inc. (OTCBB: DORB) (“DOR” or the “Company”), a late-stage biopharmaceutical company developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines against certain bioterrorism agents, announced today that the second summary of clinical trials of its drug orBec® (oral beclomethasone dipropionate, or oral BDP) for the treatment of gastrointestinal Graft-versus-Host disease (GI GVHD) has been published in the September issue of peer-reviewed medical journal Expert Opinion on Investigational Drugs. The publication “Oral Beclomethasone Dipropionate, a Topically Active Corticosteroid for Treatment of Gastrointestinal Graft-vs.-Host-Disease,” is authored by María Díez-Campelo, Fermín M Sánchez-Guijo & José A Pérez Simón of the University Hospital of Salamanca, Spain. The full article is available online at: http://www.informapharmascience.com/doi/abs/10.1517/13543784.17.9.1389.
